Degarelix Loading and Maintenance Dosing Without Testosterone Flare
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for prostate cancer using GnRH agonists and antagonists face issues such as testosterone spikes, severe side effects like cardiac disorders, urinary tract infections, and increased risk of non-prostate cancer-related mortality, despite declining prostate cancer mortality rates.
Innovation Solution
Administering a low dose of degarelix GnRH antagonist every 28 days, starting with 240 mg followed by a maintenance dose of 80 mg, to suppress testosterone levels effectively without causing a testosterone spike and minimize side effects like cardiac disorders and urinary tract infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GnRH agonists are used to treat prostate cancer, then testosterone levels are suppressed, but a testosterone spike occurs initially worsening the condition
Solution Approach 1:
The patent inverts the conventional approach by using a GnRH antagonist instead of an agonist. The antagonist directly blocks GnRH receptors without causing the initial stimulation and subsequent testosterone surge that characterizes agonist therapy, thereby achieving testosterone suppression from the first dose without the harmful flare reaction.
Solution Approach 2:
The patent applies preliminary anti-action by administering an antiandrogen before or with the GnRH antagonist to preemptively block androgen receptors. This prevents any potential androgen effects during the transition period and ensures immediate therapeutic benefit without waiting for testosterone levels to decline.
2Speed
If GnRH antagonists are used to suppress testosterone, then testosterone levels decrease rapidly, but severe side effects like cardiac disorders and urinary tract infections occur
Solution Approach 1:
The patent changes the dosing parameters by using a lower maintenance dose (80 mg every 28 days) compared to traditional GnRH antagonist regimens. This parameter adjustment maintains effective testosterone suppression while reducing the intensity and frequency of side effects such as cardiac disorders and urinary tract infections.
Solution Approach 2:
The patent implements periodic action through monthly dosing intervals (every 28 days). This periodic administration maintains therapeutic testosterone levels while allowing the body to recover between doses, thereby reducing cumulative side effects compared to continuous or more frequent dosing regimens.
3Reliability
If traditional dosing regimens are used, then testosterone suppression is achieved, but the treatment complexity and monitoring requirements increase
Solution Approach 1:
The patent segments the treatment into two distinct phases: an initial loading dose (240 mg) to rapidly achieve therapeutic effect, followed by a simplified maintenance phase (80 mg every 28 days). This segmentation allows for rapid initial control followed by a straightforward, low-complexity maintenance regimen that is easier to administer and monitor.
Solution Approach 2:
The patent enables self-service by establishing a self-regulating dosing interval of 28 days that aligns with the drug's pharmacokinetics. This fixed interval requires minimal adjustment or monitoring, allowing the treatment regimen to effectively self-regulate testosterone suppression without complex monitoring protocols or frequent dose modifications.
Data Source
AI summary
The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.